Avedro’s long saga with the FDA continues. Last week, the firm resubmitted the NDA for its riboflavin ophthalmic solution/KXL System, which should be the final step toward the company securing FDA approval. Founder and CEO David Muller explains how the Avedro worked to overcome the latest setback and how he, as the company’s leader, manages expectations of employees, investors, and customers as the company suffers delay after delay. He also gives an update on Avedro’s promising Photorefractive Intrastromal Cross-Linking (PiXL) refractive technology and explains what he learned about himself while running a dairy farm in Vermont.